Phase II Study of MK-2206 in Patients With Relapsed Lymphoma

Trial Profile

Phase II Study of MK-2206 in Patients With Relapsed Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 15 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top